HomeCompareIMHDF vs PFE

IMHDF vs PFE: Dividend Comparison 2026

IMHDF yields 2.08% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMHDF wins by $75.72M in total portfolio value
10 years
IMHDF
IMHDF
● Live price
2.08%
Share price
$19.34
Annual div
$0.40
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$75.77M
Annual income
$69,358,485.91
Full IMHDF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — IMHDF vs PFE

📍 IMHDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMHDFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMHDF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMHDF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMHDF
Annual income on $10K today (after 15% tax)
$176.65/yr
After 10yr DRIP, annual income (after tax)
$58,954,713.02/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, IMHDF beats the other by $58,932,393.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMHDF + PFE for your $10,000?

IMHDF: 50%PFE: 50%
100% PFE50/50100% IMHDF
Portfolio after 10yr
$37.91M
Annual income
$34,692,372.31/yr
Blended yield
91.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IMHDF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.9
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMHDF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMHDFPFE
Forward yield2.08%6.13%
Annual dividend / share$0.40$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$75.77M$49.6K
Annual income after 10y$69,358,485.91$26,258.71
Total dividends collected$75.26M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: IMHDF vs PFE ($10,000, DRIP)

YearIMHDF PortfolioIMHDF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,116$415.66$9,153$693.39+$2.0KIMHDF
2$12,757$863.61$8,593$849.25+$4.2KIMHDF
3$15,503$1,852.63$8,336$1,066.78+$7.2KIMHDF
4$20,796$4,208.13$8,437$1,384.80+$12.4KIMHDF
5$32,803$10,551.31$9,013$1,875.40+$23.8KIMHDF
6$66,209$31,108.90$10,306$2,680.72+$55.9KIMHDF
7$188,205$117,361.62$12,820$4,101.38+$175.4KIMHDF
8$824,954$623,575.28$17,673$6,826.70+$807.3KIMHDF
9$5,991,684$5,108,982.65$27,543$12,591.86+$5.96MIMHDF
10$75,769,588$69,358,485.91$49,560$26,258.71+$75.72MIMHDF

IMHDF vs PFE: Complete Analysis 2026

IMHDFStock

Isetan Mitsukoshi Holdings Ltd., together with its subsidiaries, engages in the department store business in Japan and internationally. The company operates through Department Store Business, Credit & Finance Business/Customer Organization Management Business, Real Estate Business, and Other Business segments. It is involved in the credit card, insurance, and other businesses; constructs and manages underground garages, public underground passages, and underground shopping malls; leases shops; operates restaurants; operates shares and business management; and construction and design, construction management, renovation and interior furniture, building maintenance, and environment production businesses. The company also engages in the supermarket, retail, and specialty shops; food production; wholesaling business; the operation of airport-style duty free shops; and provision of personnel, employment agency, recruitment office, education and training, and labor and welfare services, as well as information systems solutions. In addition, it plans, develops, imports, and sells gifts, novelty, and lifestyle goods; imports and wholesales western wine and spirits, foods, and miscellaneous products; and sells foodstuffs, clothing, and other daily goods. Further, the company plans, produces, promotes, and sells commercials, video signs, TV programs, movies, plays, entertainment and fashion shows, parties, etc.; engages in advertising agency business; plans and sells travel products and conducts tours; and owns and operates river cruise ships. The company was incorporated in 2008 and is headquartered in Tokyo, Japan.

Full IMHDF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IMHDF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMHDF vs SCHDIMHDF vs JEPIIMHDF vs OIMHDF vs KOIMHDF vs MAINIMHDF vs JNJIMHDF vs MRKIMHDF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.